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Innate immune sensing in the tumor microenvironment
is a critical step in promoting tumor infiltrating lympho-
cytes (TILs) and spontaneous anti-tumor T cell priming.
Transcriptional profiling analysis of melanoma patients
has revealed that tumors with a T cell-inflamed immu-
nophenotype are characterized by a type I IFN (IFN)
transcriptional signature. Studies in mice support the
notion that IFN produced by tumor-resident dendritic
cells (DCs) plays a critical role in spontaneous T cell
priming against tumor antigens, which is dependent
upon the host STING pathway. Preliminary data using
the mouse STING agonist DMXAA injected intratumo-
rally (IT) revealed potent tumor regression and induc-
tion of a robust anti-tumor T cell response. However,
DMXAA does not engage human STING, necessitating
alternative pharmacologic approaches to stimulate this
pathway for clinical translation. We therefore synthe-
sized a panel of cyclic dinucleotides (CDNs) that varied
by purine nucleotide base, internucleotide phosphate
bridge linkage, or by substitution of non-bridging
oxygen atoms in the phosphate bridge with sulfur. We
screened and selected from among these compounds
based on their capacity to activate all known human
STING alleles expressed in stably transformed reporter
cell lines, stimulate the activation of human PBMCs, and
impact significant antitumor efficacy in several mouse
tumor models, without significant local or systemic
toxicity. Strikingly, direct IT injection of particular CDN
derivative molecules into two week-established flank B16
melanoma, CT26 colon, or 4T1 breast tumors profoundly
inhibited tumor growth that was durable and correlated
with induction of lasting systemic antigen-specific CD8+ T
cell immunity that conferred complete protection against
tumor re-challenge, or significantly inhibited the growth of
distal untreated tumors. Induction of cytokines, tumor
antigen-specific immunity, and antitumor efficacy was
entirely STING-dependent. We selected dithio-[Rp,Rp]-c
[A(2’,5’)pA(3’,5’)p], a synthetic CDN molecule that has
significantly higher activity than natural STING ligands, as
the lead molecule for continued development. The syn-
thetic CDN molecule described here was significantly
more potent than IT TLR ligands, indicating its high
translational potential as an approach to elicit effective
unbiased T cell priming against an individual’s unique
tumor antigen repertoire.
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